{"id":"54ef033998b9","type":"article","url":"https://hartvaat.nl/2016/11/01/intensieve-bloeddrukbehandeling-120-80-mmhg-antagonist-standpunt/","title":"Intensieve bloeddrukbehandeling <120/80 mmHg: antagonist-standpunt","title_en":"Should Patients With Cardiovascular Risk Factors Receive Intensive Treatment of Hypertension to <120/80 mm Hg Target? An Antagonist View From the HOPE-3 Trial (Heart Outcomes Evaluation-3).","category":"preventie","category_label":"Preventie","professions":["cardioloog","huisarts","internist"],"tags":["bloeddrukbehandeling"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.116.023264","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.116.023264","authors":["Eva M Lonn","Salim Yusuf"],"significance":7,"published":"2016-11-01","source_date":"2016-11-01","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lipidenmedicatie-bij-ckd/","https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/"],"congress":"","summary_en":"This contra perspective argued against universal intensive blood pressure targets of <120/80 mmHg, citing risks of overtreatment, adverse effects, and the limited applicability of SPRINT to many patient populations.","created":"2026-07-03T10:26:24Z","updated":"2026-07-03T13:25:43Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Contra-argumentatie tegen universele intensieve bloeddrukbehandeling tot <120/80 mmHg. Wijst op risico's van overbehandeling, bijwerkingen en beperkte generaliseerbaarheid van SPRINT.","abstract_original":""}